白癜风对局部应用芳烃受体激动剂他扎罗芬（WBI-1001）有反应。 - Suppr

Suppr

超能文献

Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001).

作者信息

Liu Lisa, Yang Qianli, Su Ming-Wan, Zhou Youwen

机构信息

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

出版信息

JAAD Case Rep. 2023 Jul 26;39:150-151. doi: 10.1016/j.jdcr.2023.06.051. eCollection 2023 Sep.

DOI:10.1016/j.jdcr.2023.06.051

PMID:37693929

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10491801/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/032e/10491801/72f712f9ebd6/gr1.jpg

相似文献

Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001).

JAAD Case Rep. 2023 Jul 26;39:150-151. doi: 10.1016/j.jdcr.2023.06.051. eCollection 2023 Sep.

Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.

J Drugs Dermatol. 2023 Aug 1;22(8):779-784. doi: 10.36849/jdd.7317.

Tapinarof to treat psoriasis.

Drugs Today (Barc). 2020 Aug;56(8):515-530. doi: 10.1358/dot.2020.56.8.3168447.

Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.

J Am Acad Dermatol. 2021 Apr;84(4):1059-1067. doi: 10.1016/j.jaad.2020.10.085. Epub 2020 Nov 3.

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.

J Invest Dermatol. 2017 Oct;137(10):2110-2119. doi: 10.1016/j.jid.2017.05.004. Epub 2017 Jun 6.

Tapinarof Cream 1%: First Approval.

Drugs. 2022 Jul;82(11):1221-1228. doi: 10.1007/s40265-022-01748-6.

IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.

Int J Mol Sci. 2020 Dec 10;21(24):9412. doi: 10.3390/ijms21249412.

Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials.

J Drugs Dermatol. 2022 Oct 1;21(10):1084-1090. doi: 10.36849/JDD.6627.

A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.

J Am Acad Dermatol. 2021 Mar;84(3):624-631. doi: 10.1016/j.jaad.2020.04.181. Epub 2020 May 21.

Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.

J Am Acad Dermatol. 2021 Mar;84(3):632-638. doi: 10.1016/j.jaad.2020.05.135. Epub 2020 Jun 2.

引用本文的文献

The Aryl Hydrocarbon Receptor (AHR): Peacekeeper of the Skin.

Int J Mol Sci. 2025 Feb 14;26(4):1618. doi: 10.3390/ijms26041618.

The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.

Arch Dermatol Res. 2024 Oct 5;316(9):659. doi: 10.1007/s00403-024-03405-2.

Aryl hydrocarbon receptor role in chronic inflammatory skin diseases: a narrative review.

Postepy Dermatol Alergol. 2024 Feb;41(1):9-19. doi: 10.5114/ada.2023.135617. Epub 2024 Feb 28.

The role of aryl hydrocarbon receptor in vitiligo: a review.

Front Immunol. 2024 Feb 1;15:1291556. doi: 10.3389/fimmu.2024.1291556. eCollection 2024.

本文引用的文献

One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.

J Am Acad Dermatol. 2022 Oct;87(4):800-806. doi: 10.1016/j.jaad.2022.06.1171. Epub 2022 Jun 27.

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629.

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.

Chin Med J (Engl). 2020 Nov 9;133(24):2905-2909. doi: 10.1097/CM9.0000000000001221.

The Role of Memory CD8 T Cells in Vitiligo.

J Immunol. 2019 Jul 1;203(1):11-19. doi: 10.4049/jimmunol.1900027.

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.

J Invest Dermatol. 2017 Oct;137(10):2110-2119. doi: 10.1016/j.jid.2017.05.004. Epub 2017 Jun 6.

Vitiligo Pathogenesis and Emerging Treatments.

Dermatol Clin. 2017 Apr;35(2):257-265. doi: 10.1016/j.det.2016.11.014.

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial.

Br J Dermatol. 2012 Apr;166(4):853-60. doi: 10.1111/j.1365-2133.2011.10775.x. Epub 2012 Mar 14.

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial.

J Eur Acad Dermatol Venereol. 2012 Dec;26(12):1516-21. doi: 10.1111/j.1468-3083.2011.04332.x. Epub 2011 Nov 12.

Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

Arch Dermatol. 2010 Apr;146(4):446-9. doi: 10.1001/archdermatol.2010.34.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001).

作者信息

Liu Lisa, Yang Qianli, Su Ming-Wan, Zhou Youwen

机构信息

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

出版信息

JAAD Case Rep. 2023 Jul 26;39:150-151. doi: 10.1016/j.jdcr.2023.06.051. eCollection 2023 Sep.

DOI:10.1016/j.jdcr.2023.06.051

PMID:37693929

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10491801/

Abstract

摘要

相似文献

Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001).

JAAD Case Rep. 2023 Jul 26;39:150-151. doi: 10.1016/j.jdcr.2023.06.051. eCollection 2023 Sep.

Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.

J Drugs Dermatol. 2023 Aug 1;22(8):779-784. doi: 10.36849/jdd.7317.

Tapinarof to treat psoriasis.

Drugs Today (Barc). 2020 Aug;56(8):515-530. doi: 10.1358/dot.2020.56.8.3168447.

Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.

J Am Acad Dermatol. 2021 Apr;84(4):1059-1067. doi: 10.1016/j.jaad.2020.10.085. Epub 2020 Nov 3.

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.

J Invest Dermatol. 2017 Oct;137(10):2110-2119. doi: 10.1016/j.jid.2017.05.004. Epub 2017 Jun 6.

Tapinarof Cream 1%: First Approval.

Drugs. 2022 Jul;82(11):1221-1228. doi: 10.1007/s40265-022-01748-6.

IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis.

Int J Mol Sci. 2020 Dec 10;21(24):9412. doi: 10.3390/ijms21249412.

Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials.

J Drugs Dermatol. 2022 Oct 1;21(10):1084-1090. doi: 10.36849/JDD.6627.

A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.

J Am Acad Dermatol. 2021 Mar;84(3):624-631. doi: 10.1016/j.jaad.2020.04.181. Epub 2020 May 21.

Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.

J Am Acad Dermatol. 2021 Mar;84(3):632-638. doi: 10.1016/j.jaad.2020.05.135. Epub 2020 Jun 2.

引用本文的文献

The Aryl Hydrocarbon Receptor (AHR): Peacekeeper of the Skin.

Int J Mol Sci. 2025 Feb 14;26(4):1618. doi: 10.3390/ijms26041618.

The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.

Arch Dermatol Res. 2024 Oct 5;316(9):659. doi: 10.1007/s00403-024-03405-2.

Aryl hydrocarbon receptor role in chronic inflammatory skin diseases: a narrative review.

Postepy Dermatol Alergol. 2024 Feb;41(1):9-19. doi: 10.5114/ada.2023.135617. Epub 2024 Feb 28.

The role of aryl hydrocarbon receptor in vitiligo: a review.

Front Immunol. 2024 Feb 1;15:1291556. doi: 10.3389/fimmu.2024.1291556. eCollection 2024.

本文引用的文献

One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.

J Am Acad Dermatol. 2022 Oct;87(4):800-806. doi: 10.1016/j.jaad.2022.06.1171. Epub 2022 Jun 27.

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629.

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.

Chin Med J (Engl). 2020 Nov 9;133(24):2905-2909. doi: 10.1097/CM9.0000000000001221.

The Role of Memory CD8 T Cells in Vitiligo.

J Immunol. 2019 Jul 1;203(1):11-19. doi: 10.4049/jimmunol.1900027.

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.

J Invest Dermatol. 2017 Oct;137(10):2110-2119. doi: 10.1016/j.jid.2017.05.004. Epub 2017 Jun 6.

Vitiligo Pathogenesis and Emerging Treatments.

Dermatol Clin. 2017 Apr;35(2):257-265. doi: 10.1016/j.det.2016.11.014.

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial.

Br J Dermatol. 2012 Apr;166(4):853-60. doi: 10.1111/j.1365-2133.2011.10775.x. Epub 2012 Mar 14.

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial.

J Eur Acad Dermatol Venereol. 2012 Dec;26(12):1516-21. doi: 10.1111/j.1468-3083.2011.04332.x. Epub 2011 Nov 12.

Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

Arch Dermatol. 2010 Apr;146(4):446-9. doi: 10.1001/archdermatol.2010.34.